Regeneron Drug Pipeline

Regeneron maintains a substantial clinical portfolio, with 97 active trials and a total of 321 trials registered since 2008. The active pipeline spans all phases of clinical development, including 35 Phase 1, 47 Phase 2, 35 Phase 3, and 2 Phase 4 trials. These programs cover 12 therapeutic areas, with a significant concentration in oncology, which accounts for 56 active trials, or 58% of the active portfolio. Within oncology, the leading indications are multiple myeloma (11 active trials, including 4 in Phase 3), non-small cell lung cancer (NSCLC) (8 active trials, including 2 in Phase 3), advanced solid tumors (8 active trials, including 1 in Phase 3), non-Hodgkin lymphoma (8 active trials, including 5 in Phase 3), and melanoma (6 active trials, including 3 in Phase 3). Beyond oncology, the company is also active in metabolic and cardiovascular diseases, each with 6 active trials, as well as immunology (3 active trials), ophthalmology (2 active trials), and CNS (2 active trials). The relatively high number of Phase 3 trials in oncology suggests a potential for near-term clinical catalysts in this area.